Floatz logo

Tunlametinib

Pancreatic Cancer Non-resectable

Chinese PLA General HospitalSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
89/ 100

Competitive context

329 Active assets in the Pancreatic Cancer Non-resectable cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Chinese PLA General Hospital
Phase 4BBB
Metformin
State University of New York - Downstate Medical Center
Phase 2BBB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
S-1
Liu Xiufeng
Phase 4BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Tunlametinib is also rated in:

melanomaDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
Solid CancersDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →